VASSILIKI A PAPADIMITRAKOPOULOU to Receptor Protein-Tyrosine Kinases
This is a "connection" page, showing publications VASSILIKI A PAPADIMITRAKOPOULOU has written about Receptor Protein-Tyrosine Kinases.
Connection Strength
0.718
-
Personalized Medicine Tackles Clinical Resistance: Alectinib in ALK-Positive Non-Small Cell Lung Cancer Progressing on First-Generation ALK Inhibitor. Clin Cancer Res. 2016 Nov 01; 22(21):5177-5182.
Score: 0.424
-
The future of NSCLC: molecular profiles guiding treatment decisions. Oncology (Williston Park). 2011 Jun; 25(7):607, 614.
Score: 0.294